CXCL9/MIG Antibody AF-492-NA from R&D Systems, a Bio-Techne Brand

Product Specs
ItemCXCL9/MIG Antibody
CompanyR&D Systems, a Bio-Techne Brand
Price $519.00Supplier Page View Company Product Page
Catalog NumberAF-492-NA
NCBI Gene Aliasescrg-10, CMK, Humig, SCYB9, MuMIG, Mig, MIG, Scyb9
ApplicationsELISA Development (Capture),Flow Cytometry,Immunohistochemistry,Western Blot,Immunohistochemistry-Paraffin,Immunohistochemistry-Frozen,In vivo assay,Neutralization,ELISA Capture (Matched Antibody Pair),Immunocytochemistry
FormatLyophilized from a 0.2 µm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS
TargetCXCL9/MIG
IsotypeIgG
Quantity100 ug (also 25 ug)
Conjugate/TagUnconjugated
ReactivityHuman,Mouse
HostGoat
NCBI Full Gene NameC-X-C motif chemokine ligand 9, chemokine (C-X-C motif) ligand 9
ClonalityPolyclonal
ImmunogenE. coli-derived recombinant mouse CXCL9/MIG, Accession # P18340
ConcentrationLYOPH
PurityAntigen Affinity-purified
Antibody TypePrimary Antibodies
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution

Specifications/Features

Available conjugates: Available conjugates: Unconjugated

Specificity: Detects mouse CXCL9/MIG in ELISAs. In sandwich immunoassays, less than 0.5% cross-reactivity with recombinant human (rh) CXCL9/MIG is observed and less than 0.005% cross-reactivity with recombinant mouse MIP-2, recombinant rat CINC-1, rhGRO alpha, rhGROß, and rhGRO gamma is observed.

Sizes Available: 100 ug (also 25 ug)

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Macrophage TRIM21 lactylation exacerbates infection-induced orchitis through enhancing STAT1-mediated CXCL9 and CXCL10 productionFrontiers in ImmunologyJanuary 14, 2026Wenjing Tang, Wenjie Chen, Na Li, Wei Li, Zhigang Lei, Wenhui Sun, Xuan Xie, Yihong Jiang, Ying Chen, Lei Xu, et al.epididymis. In situ chemokine neutralization The recombinant neutralizing antibodies anti-CXCL9 (AF-492-NA, R&D Systems, Minneapolis, MN, USA) and anti-CXCL10 (AF-466-NA, R&D Systems, Minneapolis, MN, USA) were

(2) Resident Macrophage-Orchestrated Immune and Fibroblast Interactions in Immune Checkpoint Inhibitor-Associated NephrotoxicityAdvanced science (Weinheim, Baden-Wurttemberg, Germany)November 1, 2025Ma Y, Chen Y, Yao Q, Wang Y, Ouyang N, Han F, Wang G, Wang M, Yuan Y, Chen J, et al.macrophage‐mediated T cell activation, a neutralizing anti‐CXCL9 antibody (2 µg mL−1; R&D Systems, AF‐492‐NA) was added directly to the macrophage compartment at the beginning of the co‐culture and maintained

(3) Epithelial Ikkβ deletion modulates immune responses and the IFNγ/CXCL9 axis during early esophageal carcinogenesisbioRxiv : the preprint server for biologyMarch 19, 2025Hodge N, Tétreault MP.

(4) FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and ActivationCancer researchDecember 15, 2023Ouyang Y, Ou Z, Zhong W, Yang J, Fu S, Ouyang N, Chen J, Xu L, Wu D, Qian J, et al.Thermo Fisher Scientific, RRID: AB_10984334) was performed. IHC staining for CXCL9 (diluted 1:1,000; catalog no. AF-492-NA, R&D Systems, RRID: AB_2086734) was performed for mouse tumor tissues. IHC staining for PSAT1 (diluted

(5) Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockadeDiabetologiaJuly 1, 2022Kawada-Horitani E, Kita S, Okita T, Nakamura Y, Nishida H, Honma Y, Fukuda S, Tsugawa-Shimizu Y, Kozawa J, Sakaue T, et al.(1:100, CL8942AP; Cedarlane, Canada); goat anti-mouse C-X-C motif chemokine ligand 9 (CXCL9) (1:100, AF-492-NA; R&D Systems, USA); rabbit anti-human CXCL9 (1:50, ab202961; Abcam); rabbit anti-human, mouse and rat

(6) MYC inhibition reprograms tumor immune microenvironment by recruiting T lymphocytes and activating the CD40/CD40L system in osteosarcomaCell death discoveryMarch 15, 2022Jiang K, Zhang Q, Fan Y, Li J, Zhang J, Wang W, Fan J, Guo Y, Liu S, Hao D, et al.CXCL10 in vivo, anti-mouse CCL5 (R&D Systems, MAB478, 50 μg per mouse), anti-mouse CXCL9 (R&D Systems, AF-492-NA, 50 μg per mouse), anti-mouse CXCL10 (R&D Systems, MAB466, 50 μg per mouse) or a mixture of these antibodies

(7) Activating a collaborative innate-adaptive immune response to control metastasisCancer cellOctober 11, 2021Sun L, Kees T, Almeida AS, Liu B, He XY, Ng D, Han X, Spector DL, McNeish IA, Gimotty P, et al.anti-Mouse TNF-alpha,R&D Systems,Cat #MAB4101 Goat polyclonal anti-Mouse CXCL9/MIG,R&D Systems,Cat #AF-492-NA InVivoMAb anti-mouse CD8α,BioXCell,Cat #BE0004-1 InVivoMAb anti-mouse CD4,BioXCell,Cat #BE0003-1 InVivoMAb anti-mouse CSF1R (CD115

(8) Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stressMolecular cellMay 20, 2021Zhang W, Liu W, Jia L, Chen D, Chang I, Lake M, Bentolila LA, Wang CY.anti-α-tubulin,Sigma-Aldrich,Cat#T9026; RRID: AB_477593 Goat polyclonal anti-CXCL9,R&D Systems,Cat#AF-492-NA; RRID: AB_2086734 Rabbit polyclonal anti-CXCL10,Bioss Antibodies,Cat#BS-1502R; RRID: AB_10859700 Mouse

(9) Inhibition of the CXCL9-CXCR3 axis suppresses the progression of experimental apical periodontitis by blocking macrophage migration and activationScientific reportsJanuary 28, 2021Hasegawa T, Venkata Suresh V, Yahata Y, Nakano M, Suzuki S, Suzuki S, Yamada S, Kitaura H, Mizoguchi I, Noiri Y, et al.

(10) Commensal-driven immune zonation of the liver promotes host defenceNatureJanuary 1, 2021Gola A, Dorrington MG, Speranza E, Sala C, Shih RM, Radtke AJ, Wong HS, Baptista AP, Hernandez JM, Castellani G, et al.staining was performed using Opal IHC kit (Akoya Biosciences NEL811001KT) and CXCL9-Gt (R&D Systems, Cat# AF-492-NA). Briefly, exogenous peroxidase in livers was first quenched with 0.3% hydrogen peroxide solution for

(11) Increased Osteoblastic Cxcl9 Contributes to the Uncoupled Bone Formation and Resorption in Postmenopausal OsteoporosisClinical interventions in agingJanuary 1, 2020Liu Z, Liang W, Kang D, Chen Q, Ouyang Z, Yan H, Huang B, Jin D, Chen Y, Li Q.OVX+Veh or OVX + Ab group (n=5) were injected subcutaneously with saline or anti-Cxcl9 (R&D System, #AF-492-NA, 1μg/50 μL) every other day for 2 months and then sacrificed for further analysis. The treatment was

(12) Herpes Simplex Virus Type 2 Infection-Induced Expression of CXCR3 Ligands Promotes CD4⁺ T Cell Migration and Is Regulated by the Viral Immediate-Early Protein ICP4Frontiers in immunologyJanuary 1, 2018Zhang M, Deng X, Guan X, Geng L, Fu M, Zhang B, Chen R, Hu H, Hu K, Zhang D, et al.Wuhan, China). Abs against mouse CD4, CXCL9, CXCL10, and CXCL11 were purchased from R&D Systems (MAB554, AF-492-NA, AF-466-NA, and AF-572, USA). Abs against ICP4, ICP27, gB, and HSV-2 were from Abcam (ab96431, ab53480,

(13) Herpes simplex virus-1 evasion of CD8+ T cell accumulation contributes to viral encephalitisThe Journal of clinical investigationOctober 2, 2017Koyanagi N, Imai T, Shindo K, Sato A, Fujii W, Ichinohe T, Takemura N, Kakuta S, Uematsu S, Kiyono H, et al.

(14) Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 productionJournal of leukocyte biologyJuly 1, 2017Shinde P, Liu W, Ménoret A, Luster AD, Vella AT.

(15) Salt suppresses IFNγ inducible chemokines through the IFNγ-JAK1-STAT1 signaling pathway in proximal tubular cellsScientific reportsApril 20, 2017Arai Y, Takahashi D, Asano K, Tanaka M, Oda M, Ko SBH, Ko MSH, Mandai S, Nomura N, Rai T, et al.

(16) IL-33 Attenuates Sepsis by Inhibiting IL-17 Receptor Signaling through Upregulation of SOCS3Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacologyJanuary 1, 2017Lv R, Zhao J, Lei M, Xiao D, Yu Y, Xie J.

(17) Osteoblasts secrete Cxcl9 to regulate angiogenesis in boneNature communicationsDecember 14, 2016Huang B, Wang W, Li Q, Wang Z, Yan B, Zhang Z, Wang L, Huang M, Jia C, Lu J, et al.4-week-old, three mice per each group) were subcutaneously administered mouse CXCL9 antibody (R&D System, #AF-492-NA, 1 μg per 50 μl) or rMuMig/CXCL9 (PrimeGene Bio-Tech, #221-09, 100 ng per 50 μl) every other day for

(18) A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor EffectsMolecular therapy. Nucleic acidsDecember 13, 2016Lai WY, Huang BT, Wang JW, Lin PY, Yang PC.

(19) CXCR3 Blockade Inhibits T Cell Migration into the Skin and Prevents Development of Alopecia AreataJournal of immunology (Baltimore, Md. : 1950)August 15, 2016Dai Z, Xing L, Cerise J, Wang EH, Jabbari A, de Jong A, Petukhova L, Christiano AM, Clynes R.

(20) Regulatory T cells prevent inducible BALT formation by dampening neutrophilic inflammationJournal of immunology (Baltimore, Md. : 1950)May 1, 2015Foo SY, Zhang V, Lalwani A, Lynch JP, Zhuang A, Lam CE, Foster PS, King C, Steptoe RJ, Mazzone SB, et al.(BD Biosciences, North Ryde, NSW, Australia; catalog 553086), anti-CXCL9 (R&D Systems, Minneapolis, MN; catalog AF-492-NA), anti-Foxp3 (eBioscience, San Diego, CA; catalogue 14-5773-82), anti-PVM (provided by U. Buchholz,

Be the First to Write a Review!

CXCL9/MIG Antibody

CXCL9/MIG Antibody from R&D Systems, a Bio-Techne Brand

Specifications/Features

R&D Systems, a Bio-Techne Brand

Citations (35)

Reviews

CXCL9/MIG Antibody from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map